Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Sweden / NCT06637202
Active, not recruiting Not applicable

Swebcg 91:A RT. Breast Conserving Surgery With or Without Radiotherapy for Breast Cancer Patients

NCT06637202 · tracked via the Priya Life Science Sweden tracker
Sponsor
Region Skane
Phase
Not applicable
Started
1991-01-01
Last updated
2024-10-15

Condition(s) studied

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Investigational drug(s) / intervention(s)

postoperative radiotherapy

postoperative radiotherapy: 50 Gy in 25 fractions

Study summary

The main goal of the trial was to analyse the value of radiotherapy after breast conserving surgery for patients with breast cancer, and to find groups of patients where the treatment could be omitted.

Eligibility

Sex
FEMALE
Min age
—
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * female * not over the age of 75 years * operated because of stage 1-2 invasive adenocarcinoma of the breast * radical excision of the tumour Exclusion Criteria: * earlier cancer except cancer in situ of the cervix or skin * distant metastases

Primary outcome measure(s)

  • Loco-regional recurrence — 35 years
    Recurrence in the breast or regional lymph nodes

Trial sites (1)

FacilityCityRegionStatus
Region Skane Lund Sweden

More Region Skane trials in Sweden

Sustainable Hypertension Management in Primary Health Care in Sweden Recruiting
Biomarkers After Out-of-hospital Cardiac Arrest- a STEPCARE Substudy Active, not recruiting
Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia Recruiting
The Study Tests if Preoperative Dental Screening is Superior to no Preoperative Dental Screening in Improving the Outcome of Patients Undergoing Surgical Cardiac Valve Replacement or Transcatheter Cardiac Valve Implantation. Recruiting
Evaluation of Three Tests to Assess Social Cognition in Huntington Disease Recruiting

Other trials for the same condition

Aspects of Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients - Focusing on Geriatric Screening Recruiting
Question Prompt List in Breast Cancer Patients Planned for Neoadjuvant Chemotherapy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06637202 on ClinicalTrials.gov ↗ ← All trials in Sweden